Premium
U.S. Insurance Coverage of Contraceptives and the Impact Of Contraceptive Coverage Mandates, 2002
Author(s) -
Sonfield Adam,
Gold Rachel Benson,
Frost Jennifer J.,
Darroch Jacqueline E.
Publication year - 2004
Publication title -
perspectives on sexual and reproductive health
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.818
H-Index - 93
eISSN - 1931-2393
pISSN - 1538-6341
DOI - 10.1111/j.1931-2393.2004.tb00011.x
Subject(s) - medical prescription , medicine , family planning , health insurance , population , developed country , demography , health care , family medicine , actuarial science , business , environmental health , economic growth , research methodology , economics , nursing , sociology
CONTEXT: In 1993, coverage of reversible contraception by U.S. health insurance plans was extremely low. Little is known about how coverage has changed since then, particularly in response to state mandates. METHODS: In 2001–2002, a nationally representative sample of 205 health care insurers responded to a survey about coverage of reproductive health care services in “typical” employment‐based managed care plans (excluding self‐insured plans). Data were analyzed to compare coverage in states with and without contraceptive coverage mandates, and to show trends in coverage between 1993 and 2002. RESULTS: In 2002, almost every reversible contraceptive service and supply studied was covered by at least 89% of typical plans; 86% of plans covered the five leading prescription methods (the diaphragm, one‐ and three‐month inject‐ables, the IUD and oral contraceptives). Coverage of each contraceptive service and supply studied was higher in 2002 than in 1993 (78–97% vs. 32–59%). Plans in states with mandates were significantly more likely to cover the five leading prescription methods (87–92%, depending on type of plan) than were those designed locally in states without mandates (47–61%). Between 1993 and 2002, state mandates were estimated to account for 30% and 40% of the increase in coverage of oral contraceptives and the three‐month injectable, respectively. CONCLUSIONS: Coverage of reversible contraception–and by extension, choice within a range of covered methods–has increased substantially since 1993, in part because of state mandates. This state‐by‐state approach, however, has inherent limitations that can best be dealt with at the federal level.